Novo Nordisk's CagriSema shows 25.4% mean weight loss in early responders in post hoc analysis
NVO•Post hoc REDEFINE 1 analyses showed 25.4% mean weight loss among early responders receiving Novo Nordisk’s investigational obesity treatment CagriSema. The findings were presented at ObesityWeek 2026 and are hypothesis-generating, not a basis for changing clinical decisions.
1. Post hoc findings
Novo Nordisk announced post hoc analyses of the REDEFINE 1 trial showing greater weight loss among early responders receiving CagriSema. Patients taking CagriSema also reported meaningful physical and psychosocial function improvements more often than those receiving placebo; gastrointestinal side effects predominated, and adverse-event discontinuations were more common with CagriSema.
2. Regulatory timeline
The early-response findings are hypothesis-generating and are not a basis for changing clinical decisions. A US regulatory decision on CagriSema for weight management is expected in the fourth quarter of 2026, following its December 2025 application.
